Related Experiment Video

Updated: Jan 22, 2026

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

10.3K

Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists

Chakravarthi Simhadri1, Kevin D Daze1, Sarah F Douglas1

  • 1Department of Chemistry, University of Victoria, Victoria, BC, V8P 5C2, Canada.

Chemmedchem
|June 30, 2019
PubMed

Insights

Researchers developed novel small-molecule inhibitors targeting Chromobox homolog 7 (Cbx7), an epigenetic modulator implicated in cancer. This study adapted existing L3MBTL1 inhibitors, identifying compounds with modest Cbx7 inhibitory potential for further cancer research.

Area of Science:

  • Epigenetics
  • Chemical Biology
  • Cancer Biology

Background:

  • Chromobox homolog 7 (Cbx7) is an epigenetic regulator and a key driver in various cancers.
  • Cbx7 functions as a methyl reader protein, binding to methylated lysine residues on target proteins.

Purpose of the Study:

  • To design and synthesize low-molecular-weight inhibitors of Cbx7.
  • To adapt existing inhibitors of the related methyl reader protein L3MBTL1, which were previously ineffective against Cbx7.

Main Methods:

  • Rational structural modifications of L3MBTL1 inhibitors.
  • Evaluation of Cbx7 inhibition using fluorescence polarization assays.
  • Confirmation of inhibitor binding to Cbx7 via saturation-transfer difference NMR spectroscopy.

Main Results:

  • Identification of several novel small-molecule inhibitors of Cbx7.
  • Modest inhibitory potency observed, with IC50 values ranging from 257–500 μm.
  • Validation of inhibitor binding to the target protein Cbx7.

Conclusions:

  • The study successfully generated initial Cbx7 inhibitors through structural adaptation of related compounds.
  • These findings provide a foundation for developing more potent Cbx7-targeting therapeutics for cancer treatment.
  • Further optimization is needed to enhance the potency of these small-molecule inhibitors.
Keywords:
anticancer agentsbromodomainschromatinepigeneticshistones

More Related Videos

Methodologies for Studying B. subtilis Biofilms as a Model for Characterizing Small Molecule Biofilm Inhibitors10:17

Methodologies for Studying B. subtilis Biofilms as a Model for Characterizing Small Molecule Biofilm Inhibitors

Published on: October 9, 2016

16.2K
Fluorescence-Based Detection of FEN1 Nuclease Activity and Screening of Small-Molecule Inhibitors05:46

Fluorescence-Based Detection of FEN1 Nuclease Activity and Screening of Small-Molecule Inhibitors

Published on: June 27, 2025

553

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
574
Rational Emotive Behavior Therapy01:24

Rational Emotive Behavior Therapy

Cognitive-behavioral therapies (CBTs) are grounded in the belief that our thoughts profoundly influence our emotions and actions. Advocates of CBT emphasize three core assumptions: first, that cognitions are identifiable and measurable; second, that they are central to psychological functioning; and third, that irrational or maladaptive beliefs can be replaced with rational and adaptive ones. This transformative approach to therapy has paved the way for specific models such as Albert...
382
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
918
Molecules and Compounds02:38

Molecules and Compounds

Atoms and Molecules
68.3K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.4K